The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease

被引:11
作者
Bjorklund, Anders [1 ]
Barker, Roger A. [2 ,3 ]
机构
[1] Lund Univ, Wallenberg Neurosci Ctr, Dept Expt Med Sci, BMC A11, S-22184 Lund, Sweden
[2] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge CB2 0PY, England
[3] Univ Cambridge, John van Geest Ctr Brain Repair, Dept Clin Neurosci, Cambridge CB2 0PY, England
关键词
transplantation; stem cells; 192-IgG saporin; cognitive impairment; dementia; nucleus basalis; SLEEP BEHAVIOR DISORDER; RADIAL MAZE PERFORMANCE; SERIAL REACTION-TIME; SHORT-TERM-MEMORY; QUALITY-OF-LIFE; NUCLEUS BASALIS; COGNITIVE IMPAIRMENT; EXCITOTOXIC LESIONS; ALZHEIMERS-DISEASE; IMMUNOTOXIC LESION;
D O I
10.1093/brain/awae026
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In recent years there has been a renewed interest in the basal forebrain cholinergic system as a target for the treatment of cognitive impairments in patients with Parkinson's disease, due in part to the need to explore novel approaches to treat the cognitive symptoms of the disease and in part to the development of more refined imaging tools that have made it possible to monitor the progressive changes in the structure and function of the basal forebrain system as they evolve over time. In parallel, emerging technologies allowing the derivation of authentic basal forebrain cholinergic neurons from human pluripotent stem cells are providing new powerful tools for the exploration of cholinergic neuron replacement in animal models of Parkinson's disease-like cognitive decline.In this review, we discuss the rationale for cholinergic cell replacement as a potential therapeutic strategy in Parkinson's disease and how this approach can be explored in rodent models of Parkinson's disease-like cognitive decline, building on insights gained from the extensive animal experimental work that was performed in rodent and primate models in the 1980s and 90s. Although therapies targeting the cholinergic system have so far been focused mainly on patients with Alzheimer's disease, Parkinson's disease with dementia may be a more relevant condition. In Parkinson's disease with dementia, the basal forebrain system undergoes progressive degeneration and the magnitude of cholinergic cell loss has been shown to correlate with the level of cognitive impairment. Thus, cell therapy aimed to replace the lost basal forebrain cholinergic neurons represents an interesting strategy to combat some of the major cognitive impairments in patients with Parkinson's disease dementia. Degeneration of the basal forebrain cholinergic system is a major cause of cognitive impairments and dementia in patients with Parkinson's disease. Bj & ouml;rklund and Barker summarize the extensive experimental data in support of the idea that transplants of cholinergic neurons could be used to restore cognitive function.
引用
收藏
页码:1937 / 1952
页数:16
相关论文
共 120 条
[1]   Behavioural specificity of neocortical grafts of fetal basal forebrain tissue after unilateral lesion of the nucleus basalis with alpha-amino-3-OH-4-isoxozole propionic acid (AMPA) [J].
Abdulla, FA ;
Calaminici, M ;
Gray, JA ;
Stephenson, JD ;
Sinden, JD .
BRAIN RESEARCH BULLETIN, 1997, 42 (06) :407-414
[2]  
Albin RL, 2022, PROG BRAIN RES, V269, P345, DOI 10.1016/bs.pbr.2022.01.011
[3]   Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons [J].
Allard, Simon ;
Jacobs, Marie L. ;
Do Carmo, Sonia ;
Cuello, A. Claudio .
NEUROBIOLOGY OF AGING, 2018, 67 :10-20
[4]   Basal forebrain cholinergic signalling: development, connectivity and roles in cognition [J].
Ananth, Mala R. ;
Rajebhosale, Prithviraj ;
Kim, Ronald ;
Talmage, David A. ;
Role, Lorna W. .
NATURE REVIEWS NEUROSCIENCE, 2023, 24 (04) :233-251
[5]   LOSS OF NEURONS IN THE NUCLEUS BASALIS OF MEYNERT IN ALZHEIMERS-DISEASE, PARALYSIS AGITANS AND KORSAKOFFS DISEASE [J].
ARENDT, T ;
BIGL, V ;
ARENDT, A ;
TENNSTEDT, A .
ACTA NEUROPATHOLOGICA, 1983, 61 (02) :101-108
[6]   Septal grafts restore cognitive abilities and amyloid precursor protein metabolism [J].
Aztiria, Eugenio ;
Cataudella, Tiziana ;
Spampinato, Santi ;
Leanza, Giampiero .
NEUROBIOLOGY OF AGING, 2009, 30 (10) :1614-1625
[7]   GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop [J].
Barker, Roger A. ;
Bjorklund, Anders ;
Gash, Don M. ;
Whone, Alan ;
Laar, Amber Van ;
Kordower, Jeffrey H. ;
Bankiewicz, Krystof ;
Kieburtz, Karl ;
Saarma, Mart ;
Booms, Sigrid ;
Huttunen, Henri J. ;
Kells, Adrian P. ;
Fiandaca, Massimo S. ;
Stoessl, A. Jon ;
Eidelberg, David ;
Federoff, Howard ;
Voutilainen, Merja H. ;
Dexter, David T. ;
Eberling, Jamie ;
Brundin, Patrik ;
Isaacs, Lyndsey ;
Mursaleen, Leah ;
Bresolin, Eros ;
Carroll, Camille ;
Coles, Alasdair ;
Fiske, Brian ;
Matthews, Helen ;
Lungu, Codrin ;
Wyse, Richard K. ;
Stott, Simon ;
Lang, Anthony E. .
JOURNAL OF PARKINSONS DISEASE, 2020, 10 (03) :875-891
[8]   Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe? [J].
Barrett, Matthew J. ;
Sargent, Lana ;
Nawaz, Huma ;
Weintraub, Daniel ;
Price, Elvin T. ;
Willis, Allison W. .
MOVEMENT DISORDERS CLINICAL PRACTICE, 2021, 8 (08) :1181-1188
[9]  
Baxter MG, 2001, METH MOL B, V166, P249
[10]  
BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507